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Abstract
The orexin family of hypothalamic neuropeptides has been implicated in reinforcement
mechanisms relevant to both food and drug reward. Previous behavioral studies with antagonists
at the orexin A-selective receptor, OX1, have demonstrated its involvement in behavioral
sensitization, conditioned place-preference, and self-administration of drugs of abuse. Adult male
Swiss-Webster mice were implanted with stimulating electrodes to the lateral hypothalamus and
trained to perform intracranial self-stimulation (ICSS). The effects of the OX1-selective antagonist
SB 334867 on brain stimulation-reward (BSR) and cocaine potentiation of BSR were measured.
SB 334867 (10 – 30 mg/kg, i.p.) alone had no effect on ICSS performance or BSR threshold.
Cocaine (1.0 – 30 mg/kg i.p.) dose-dependently potentiated BSR, measured as lowering of BSR
threshold. This effect was not blocked by 30 mg/kg SB 334867 at any cocaine dose tested. In
agreement with previous reports, SB 334867 resulted in a reduction of body weight 24 hours after
acute administration. Based on these data, it is concluded that orexins acting at OX1 do not
contribute to BSR; and are not involved in the reward-potentiating actions of cocaine on BSR. The
data are discussed in the context of prior findings of SB 334867 effects on drug-seeking and drug-
consuming behaviors.
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1. INTRODUCTION
Since the orexin family of hypothalamic neuropeptides were first described over a decade
ago (de Lecea et al. 1998; Sakurai et al. 1998) they have been implicated in arousal
(Adamantidis et al. 2007; de Lecea et al. 1998; Nishino 2007; Nishino et al. 2000),
appetitive behaviors (Clegg et al. 2002; Nair et al. 2008; Sakurai et al. 1998; Zheng et al.
2007); and reward processing (Aston-Jones et al. 2009; Borgland et al. 2010; Boutrel et al.
2005; DiLeone et al. 2003; Harris et al. 2005; Sharf et al. 2010b). Both orexin A (OxA) and
orexin B (OxB) are synthesized from one gene product, prepro-orexin, by hypothalamic
neurons; and act through two distinct G-protein coupled receptor systems, OX1 and OX2.
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OX1 has a significantly higher affinity for OxA, while OX2 has similar affinity for OxA and
OxB (Sakurai et al. 1998).
Orexin-containing neurons projecting from the lateral hypothalamus (LH) to the
mesencephalic ventral tegmental area (VTA; (Peyron et al. 1998) have been shown to be
involved in drug preference (Harris et al. 2005) and reinstatement of drug self-
administration following extinction (Boutrel et al. 2005; Smith et al. 2009). These findings
can be partially explained by the observation that orexins increase firing rate and/or promote
burst firing of dopaminergic VTA neurons (Korotkova et al. 2003) thereby facilitating
dopamine release in brain regions receiving VTA projections (Narita et al. 2006; Vittoz and
Berridge 2006; Vittoz et al. 2008). Both OxA and OxB enhance glutamatergic signaling in
the VTA, although OxA appears to preferentially affect synaptic transmission associated
with positive reinforcers (Borgland et al. 2009; Borgland et al. 2008).
Intracranial self-stimulation (ICSS) is an operant behavioral method in which animals are
trained to deliver reinforcing electrical stimulation (brain stimulation reward, or BSR) to
discrete elements of brain reward circuitry. Specifically, mice self-stimulate the medial
forebrain bundle (MFB) in the LH, which includes ascending dopaminergic fibers from the
VTA to the limbic forebrain, particularly the nucleus accumbens (NAc) and prefrontal
cortex (Wise 2002). The MFB is also adjacent to orexin neurons of the LH, raising the
possibility that orexin release itself plays a role in BSR (DiLeone et al. 2003; Lawrence
2010). The ability of drugs to potentiate or attenuate the rewarding value of BSR can be
determined by measuring ICSS responses after acute or chronic drug treatment. Acute
administration of drugs of abuse, regardless of their pharmacological class, potentiates the
rewarding value of BSR (Kornetsky and Bain 1992; Kornetsky and Duvauchelle 1994).
In these experiments, we investigated the effects of the OX1 antagonist SB 334867 (SB) on
BSR and cocaine reward using ICSS. This orexin antagonist has been shown to reduce home
cage feeding (Clegg et al. 2002; Zheng et al. 2007) and decrease operant self-administration
of high-fat containing food (Borgland et al. 2009; Nair et al. 2008). SB does not decrease
fixed-ratio cocaine self-administration (Espana et al. 2010; Smith et al. 2009), but does
decrease breakpoint on progressive-ratio schedules of cocaine self-administration (Borgland
et al. 2009; Espana et al. 2010), suggesting that OX1 antagonism may reduce the rewarding
value of cocaine (Richardson and Roberts 1996). SB also blocks stress- and cue-induced but
not drug-induced reinstatement of cocaine self-administration after extinction (Boutrel et al.
2005; Smith et al. 2009). To test the hypothesis that OX1 antagonism decreases the reward-
potentiating effect of cocaine on BSR, we measured changes in BSR threshold (θ0) and
maximum operant response rates following SB administration alone and before cocaine.
2. RESULTS
2.1 Effects of SB 334867 on Body Weight
Consistent with its previously-reported anorexic effects, mice lost weight after acute
intermittent administration of SB (Figure 1A). Body weights were decreased 24 hours after
each dose of SB, and a significant main effect of SB treatment was seen (F(3,46) = 3.41, P <
0.05), although the dose-dependence of this effect was non-significant (SB 30 mg/kg vs. 10
mg/kg, P = 0.069). Daily average body weights aligned to the first dose of SB are shown in
Figure 1B. On day 14 all mice (n = 13) received SB (10, 20 or 30 mg/kg); 10/13 mice
received SB on day 16; 7/13 on day 18; and 6/12 on day 20; after which no more than 5/12
mice received SB on any given experimental day. By day 17 more than half of the mice
(7/13) had lost an average of 3.2 ± 1.1 g (P = N.S.) from the day prior to the first SB dose.
By day 20, average body weight returned to pre-SB levels and remained constant through
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day 31, after which no further SB experiments were performed and average daily weights
subsequently increased.
2.2 Effects of SB 334867 on Brain Stimulation Reward
As we have previously shown, cocaine produces orderly leftward shifts of the ICSS rate-
frequency curve in outbred Swiss-Webster mice (Figure 2). Acute administration of SB
alone (10, 20 or 30 mg/kg i.p.) had no significant independent effect on θ0 (F(3,50) < 1.0, P >
0.5) or maximum operant response rate (F(3,50) < 2.6, P > 0.1; Figure 3). Acute
administration of cocaine (Figure 4, white circles) significantly lowered θ0 (Min. 1–15:
F(4,119) = 2.6, P < 0.05; Min. 16–30: F(4,119) = 2.9, P < 0.05) with a potency and time course
similar to our previous reports in this outbred strain of mice (Gilliss et al. 2002; Malanga et
al. 2008). When administered 30 minutes prior to acute cocaine (Figure 4, black circles), SB
(30 mg/kg) increased the reward-potentiating effect of 3.0 mg/kg cocaine during the first 30
minutes of recording (Min. 1–15: P < 0.001; Min. 16–30: P < 0.01 vs. cocaine alone), but no
parallel horizontal shift of the dose-response curve to cocaine on BSR was observed; that is,
no differences in cocaine effects on θ0 were seen between pretreatment with vehicle or 30
mg/kg SB at any time point after administration of 1.0, 10 or 30 mg/kg cocaine.
During ICSS training and testing the current amplitude is kept constant; however, the
frequency range for each animal is adjusted prior to drug testing such that only the highest
4–6 frequencies sustain responding. Therefore, comparison of θ0 expressed as electrical
charge delivery (in Coulombs, C) is a more robust comparison of baseline reward function
across days (see 4.2 Intracranial Self-Stimulation, below) or between treatment and
control groups. Every-other day testing with SB did not progressively change baseline θ0
over the course of the full experiment (Figure 5).
3. DISCUSSION
Orexins directly increase the excitability of dopaminergic VTA neurons in vitro (Borgland
et al. 2008; Borgland et al. 2006; Korotkova et al. 2003), and systemic administration of the
OX1 antagonist SB reduces spontaneous and evoked activity of dopaminergic neurons in
vivo (Moorman and Aston-Jones 2010; Rasmussen et al. 2007). However, we observed no
effect of systemic administration of SB alone at doses up to 30 mg/kg on BSR threshold (θ0)
or maximum operant response rate. Three prior reports investigated the role of orexins in
BSR in rats using rate- or discrete trial-based measures of ICSS. BSR threshold was
significantly elevated by intraventricular (Boutrel et al. 2005) or intra-VTA infusion of OxA
(Hata et al. 2011), an effect which may be due to orexin-mediated release of corticotropin-
releasing factor (CRF; Hata et al. 2011; Macey et al. 2000). However, systemic doses up to
6 mg/kg of SB alone did not affect BSR threshold but did block the reward-potentiating
effect of nicotine on BSR (Hollander et al. 2008). We conclude from our data that while
electrical self-stimulation of the LH elicits BSR in mice, direct stimulation of orexinergic
neurons in the LH and subsequent release of orexins acting at the OX1 receptor does not
contribute to BSR, consistent with recent findings that ICSS alone does not activate
significant numbers of lateral hypothalamic orexinergic neurons (Hata et al. 2011). Based on
the lack of effect of SB on maximum operant response rates we conclude that ICSS
performance is unaffected by OX1 antagonism. However, because SB was only given to
mice that had already learned to respond for BSR, we cannot determine from these data
whether OX1 antagonism would interfere with the instrumental learning processes necessary
to acquire operant responding for BSR.
Given its low aqueous solubility, it is reasonable to question the absorption and distribution
of SB after intraperitoneal injection. We solubilized SB in DMSO and cyclodextrin similar
to other laboratories performing whole-animal pharmacology experiments with similar SB
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doses (Borgland et al. 2009; Borgland et al. 2006; Boutrel et al. 2005; Espana et al. 2010;
Harris et al. 2005; LeSage et al. 2010). Consistent with prior reports (Haynes et al. 2002;
Haynes et al. 2000; Rodgers et al. 2001), we observed reductions in body weight 24 hours
after acute SB administration. This suggests that under our solubilization conditions and at
these doses, SB is systemically absorbed, crosses the blood-brain barrier, and affects feeding
behavior. While it is possible that this overnight reduction in body weight, which may
reflect an acute anorexic effect of SB, is due to peripheral effects such as reduction in
gastrointestinal motility, interruption of normal enteric peptide hormone activity, or changes
in glucocorticoid balance, all of which are affected by OxA (Baccari 2010; Heinonen et al.
2008; Kagerer and Johren 2010), this was not directly addressed in these experiments.
Our data show that SB has no significant effect on the dose-response relationship of cocaine
potentiation of BSR in Swiss-Webster mice, unlike its ability to block potentiation of BSR
by nicotine in rats (Hollander et al. 2008). Potentiation of BSR by cocaine was slightly
increased at one dose (3.0 mg/kg) in the presence of SB; however, the dose-response curve
of cocaine on BSR was otherwise unaffected by SB, with no changes observed at 1.0, 10 or
30 mg/kg cocaine at any time point after injection. Thus, SB pretreatment results in no
horizontal shift of the dose-response curve of cocaine at half-log dose increments.
Additional doses at quarter-log increments (i.e., 5.6 mg/kg) were not given, as the dose-
response relationship to cocaine is shallow in this strain compared to C57BL/6J or DBA/2J
mice, in which the cocaine dose-response curve is steeper (Fish et al. 2010). These findings
are in direct contrast to the inhibitory effects of SB on cocaine potentiation of BSR we
hypothesized based on the finding that SB reduces of breakpoints in progressive-ratio (PR)
cocaine self-administration suggesting that OX1 signaling contributes to cocaine reward
(Borgland et al. 2009; Espana et al. 2010).
The effects of SB on reward-relevant behaviors are complex, varying with both the drug and
the conditions under which they are tested (see summary in Table 1; reviewed in Sharf et al.
2010b). SB attenuates the development of conditioned place-preference to amphetamine
(Hutcheson et al. 2011) and morphine (Harris et al. 2005; Narita et al. 2006; Sharf et al.
2010a), but neither to cocaine (Sharf et al. 2010a) nor alcohol (Shoblock et al. 2011;
Voorhees and Cunningham 2011). SB also blocks the development of behavioral
sensitization to amphetamine (Quarta et al. 2010) and cocaine (Borgland et al. 2006) but not
to morphine (Sharf et al. 2010a). While SB reduces fixed-ratio (FR) self-administration of
nicotine as well as BSR potentiation by nicotine (Hollander et al. 2008; LeSage et al. 2010),
FR cocaine self-administration and, based on our data, BSR potentiation by cocaine are
unaffected by SB (Espana et al. 2010; Smith et al. 2009). However, as for nicotine
(Hollander et al. 2008), breakpoints for PR cocaine self-administration are reduced by SB
(Borgland et al. 2009; Espana et al. 2010). SB also prevents stress- and cue-induced but not
drug-induced reinstatement of both cocaine (Boutrel et al. 2005; Smith et al. 2009) and
alcohol self-administration (Lawrence et al. 2006; Richards et al. 2008) after extinction.
There are two caveats regarding the interpretation of our data in light of these previous
reports. First, both rate-dependent and rate-independent measures of ICSS (Hollander et al.
2008) demonstrate no effect of SB on BSR itself, confirming that orexin release from lateral
hypothalamic neurons is unlikely to contribute to BSR (Hata et al. 2011). However, unlike
in BSR, the role of OX1 signaling in drug reward appears to vary with the pharmacological
mechanism of the drug of abuse tested (Sharf et al. 2010a; Sharf et al. 2010b), the potency
of the drug in question as a primary reinforcer, or both. Second, unlike cocaine reward
measured with self-administration, in which cocaine itself is the primary reinforcer, in ICSS
BSR is the primary reinforcer, the potency of which is increased by cocaine. Using this
method we are able determine if and how much cocaine potentiates the value of the primary
reinforcer, BSR, but not the absolute reinforcing efficacy of cocaine in and of itself; that is,
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not the ability of cocaine to act as a primary reinforcer. With these caveats, our data support
the conclusion that antagonism of the OX1 receptor does not attenuate the rewarding
potency of cocaine measured with ICSS.
The idea that orexin signaling is involved in effort related to acquisition of high-value
rewards as opposed to less potent reinforcers has experimental support (Borgland et al.
2009). In this view, orexin signaling acts as a behavioral high-pass filter, such that the
motivation to acquire rewards with low salience, or for which the ratio of effort required to
the value of the reinforcer is high, is preferentially affected by OX1 antagonism. This
formulation does not explain why SB would block place conditioning to amphetamine and
opioids but not cocaine, which may be related to a role for OX1 signaling in learning
mechanisms. However, it does explain why SB attenuates self-administration of alcohol and
nicotine - both relatively low-potency primary reinforcers for rodent self-administration – on
an FR schedule, but only blocks cocaine self-administration on a PR schedule, where the
behavioral cost to attain a high-value reinforcer is increased. Investigation into the effects of
OX1 antagonism on amphetamine and opioid self-administration would be informative in
this regard. This formulation predicts that an OX1 antagonist would reduce breakpoints on
PR self-administration of amphetamine or heroin – both high-potency primary reinforcers -
but may also reduce self-administration of morphine, an opioid with lower reinforcing
potency than heroin, on an FR schedule. This model is also consistent with the lack of SB
effects on BSR itself, in that BSR is undoubtedly a primary reinforcer of extremely high
potency. It may also explain the effects of SB on cue- and stress-induced reinstatement of
drug self-administration, in which negative (i.e., stress) or positive (i.e., environmental
context) stimuli of relatively lesser salience compared to drug reward fail to induce drug
seeking after OX1 antagonism, but reinstating stimuli with higher potency and a lower
behavioral cost to the animal (i.e. non-contingent drug administration) are unaffected.
An alternative explanation for our data is based on the anatomical distribution and sites of
action of OX1. Mapping of mRNA for orexin receptors has shown that OX2 but not OX1 is
expressed in the NAc, while both OX1 and OX2 are expressed in the VTA (Marcus et al.
2001; Trivedi et al. 1998). One proposed model of orexin actions on drug-seeking behaviors
suggests a different role of orexin signaling for drugs of abuse with a primary site of action
in the VTA (e.g., opioids) compared to those with a primary site of action in the NAc (e.g.,
cocaine; see Figure 7 in Aston-Jones et al. 2009). Dopamine release in the NAc is clearly a
final common pathway in ICSS, although both direct stimulation of ascending dopaminergic
fibers from the VTA (Cheer et al. 2007; Kuhr et al. 1987) and indirect activation of
dopaminergic VTA neurons through stimulation of descending glutamatergic fibers
(Herberg and Rose 1990; You et al. 2001) and activation of cholinergic relays from pontine
tegmental nuclei (Chen et al. 2006; Yeomans et al. 1985) have been implicated. Because the
reward-potentiating activity of cocaine on BSR may be more closely related to its activity at
dopaminergic terminals than on VTA neuronal firing rate, it may be the case that
antagonism of VTA OX1 receptors is insufficient to overcome the direct effect of cocaine on
forebrain terminal release. In contrast, the reward-potentiating effect of nicotine is likely
related to its activation of VTA firing through both direct stimulation of nAChRs on
dopaminergic VTA neurons (Yeomans and Baptista 1997) and indirect activation of
cholinergic afferents to VTA (Chen et al. 2006), which may explain why BSR potentiation
by nicotine, but not cocaine, is blocked by SB. Experiments using transgenic mice in which
orexin receptor expression is selectively inactivated in specific neuronal populations
(Mochizuki et al. 2011) or the use of optogenetics to stimulate or inhibit endogenous orexin
release in a site-specific manner (Rolls et al. 2011) will be helpful in dissecting orexin
mechanisms in drug reward, and will clarify the brain circuits within which orexin signaling
is important for the behavioral effects of abused drugs with different cellular targets and
mechanisms of action (Yamanaka and Tsunematsu 2010).
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Manipulation of orexin signaling remains a target of significant therapeutic interest for both
drug- and food-related addictive disorders. Given the apparent complexity of the actions of
orexins in reward processing, significant further study of the role of orexins in drug- and
context-specific neural activity, including their role in basic learning mechanisms, will be
necessary before orexin antagonists are positioned to be safely considered for clinical trials.
However, the observations that OX1 antagonism does not reduce brain reward but does
block stress- and cue-induced reinstatement of drug-seeking suggests that this class of
compounds may be useful additions to stress-reduction and other behavioral therapies in the
treatment of substance abuse disorders.
4. EXPERIMENTAL PROCEDURE
4.1 Animal Care and Handling
All experimental animal procedures were carried out according to the NIH Guide to the
Care and Use of Laboratory Animals and were approved by the Institutional Animal Care
and Use Committee at the University of North Carolina at Chapel Hill.
4.2 Intracranial Self-Stimulation (ICSS)
Fifteen male white Swiss-Webster mice (Taconic Labs, Hudson NY) P50–P60 or weighing
>25g were anesthetized (ketamine/xylazine 120/18 mg/kg i.p.; Sigma, St. Louis MO) and
stereotaxically implanted with an insulated monopolar stainless steel electrode (0.28 mm
diameter; Plastics One, Roanoke VA) to the right MFB at the level of the LH (Figure 6)
using coordinates from Paxinos and Franklin (1996): bregma −2.0 mm (a/p), sagital −0.8
mm (m/l) and depth −4.5 mm (d/v). A stainless steel screw (electrical ground) and the
electrode assembly were secured to the skull with dental cement. After recovery, mice were
individually housed in polycarbonate cages (28 × 17 × 14 cm) lined with cob bedding and
covered with stainless steel wire lids. Mice were allowed free access to dry food (Purina
rodent chow) and tap water ad libitum. The vivarium was kept at 21±1°C and 30–40%
humidity on a 12-hour light/dark cycle (lights off at 8:00 AM). All ICSS experiments were
performed during the dark cycle, and began approximately 4 hours into the active phase.
One week after implantation mice were trained on a continuous (FR-1) schedule of
reinforcement for brain stimulation reward (BSR) in a 16 × 14 × 13 cm operant chamber
with a wheel manipulandum and a house light (MedAssociates, St. Albans VT). Each
quarter-turn of the wheel earned a 500 msec train of unipolar cathodal square-wave current
at a frequency of 158 Hz (pulse width = 100 µsec) and activated the house light for 500
msec. Subsequent responses during the 500 msec did not earn additional stimulation.
Optimal stimulus intensity to sustain reliable responding (≥40 responses/min) was
determined for animals individually during training, and varied between −90 and −220 µA.
Current intensity was kept constant for each animal for all experiments. One mouse failed to
reliably respond for BSR during training and was not used for subsequent experiments.
Mice were then presented a series of training stimulus frequencies in descending order from
158 Hz to 19 Hz in discrete 0.05 log10 increments (i.e., log10[112Hz] = 2.05; log10[100Hz]
= 2.00, etc.). At each frequency, five non-contingent priming stimuli were followed by 50
sec ad libitum access to BSR delivered on an FR-1 schedule during which responses were
measured. A 5 sec time-out period followed each trial frequency during which responses
earned no additional stimulation. Mice were trained to complete four series of 15 trial
frequencies (i.e., one hour daily). After training, the range of frequencies was adjusted for
each mouse such that only the highest 4–6 frequencies would sustain responding. For each
series of 15 stimulus frequencies, the rate of operant responding for BSR was plotted (i.e.,
the rate-frequency curve, see Figure 3). BSR threshold (θ0) was defined as the X-intercept of
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the least-squares regression line through frequencies that sustained responding at 20, 30, 40,
50 and 60% of the maximal response rate in each series, and was calculated automatically
by custom-designed software at the end of each experiment. This method of reward
threshold determination is less sensitive to changes in response rate than other calculations,
e.g., the frequency sustaining ½ - maximal response, or EF50 (Miliaressis et al. 1986).
Saline injections began in each animal when its mean BSR threshold varied <±10% over
three consecutive days.
On each testing day, three series of 15 frequencies were acquired before injection with
vehicle or drug. The first series served as a warm-up and was discarded; θ0 and maximum
rate from the second and third rate-frequency curves were averaged and used as baselines.
The OX1 antagonist SB 334867 (SB; Tocris Bioscience, Ellisville MO) was solubilized in
DMSO (20% v/v) and hydroxypropyl β-cyclodextrin (25% w/v) in sterile normal (0.9%)
saline and was prepared fresh daily. SB and cocaine HCl (in sterile normal saline; Sigma)
were administered by intraperitoneal injection. In initial experiments, θ0 and maximum
response rates were measured for four 15-minute series immediately following SB (10, 20 or
30 mg/kg) or vehicle injection. In subsequent experiments, mice were injected with SB (30
mg/kg) or vehicle and two 15-minute series were acquired, followed by injection with
cocaine (1.0, 3.0, 10 or 30 mg/kg, calculated as the free base) and acquisition of four
additional 15-minute series. Pretreatment with SB for 30 minutes prior to various behavioral
measurements is within the range commonly reported by several other laboratories
(Borgland et al. 2009; Harris et al. 2005; Lawrence et al. 2006; Richards et al. 2008; Sharf et
al. 2010a). Mice were tested with drug every other day and with saline or vehicle injections
on alternate days. For each drug tested, doses were presented in random order. All data were
analyzed as percent changes from baseline θ0 or maximum response rate on that day. One
mouse died between the SB and SB + cocaine experiments and one mouse lost its electrode
headstage before the completion of full SB + cocaine dose-response determinations, for a
final n of 12 mice.
4.3 Histology
At the end of all experiments, brains were fixed with paraformaldehyde (4% w/v in 0.1M
phosphate buffered saline) and serial coronal frozen sections (50 µm) were collected through
the ICSS electrode tract, mounted onto Superfrost Plus (Fisher Scientific, Pittsburgh PA)
slides; stained with cresyl violet for Nissl; and viewed under low-power (4X) light
microscopy for confirmation of electrode tip placements (Figure 6).
4.4 Statistical Analysis
One-way ANOVA was used to determine effects of SB 334867 administration on body
weight. Two-way ANOVA (dose × time after injection) with post-hoc (Bonferroni)
comparisons for significant main effects was used to determine effects of drugs on BSR
threshold (θ0) and maximum operant response rate.
HIGHLIGHTS
▶ Orexin signaling is involved in the rewarding effects of drugs of abuse.
▶ Effects of the OX1 receptor antagonist SB 334867 were investigated in
outbred mice.
▶ SB 334867 does not affect electrical brain stimulation reward (BSR) in mice.
▶ SB 334867 does not block the ability of cocaine to potentiate BSR in mice.
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MFB Medial forebrain bundle
NAc Nucleus accumbens
SB 334867 N-(2-Methyl-6-benzoxazolyl)-N'-1,5-naphthyridin-4-yl urea
VTA Ventral tegmental area
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A. Interval change in body weight (mean ± SEM) measured 24 hours after each dose of the
orexin-A receptor antagonist SB 334867. * P < 0.05 vs. vehicle (V). B. Average daily
weight of all mice (n = 12–13) ± SEM before, during and after administration of SB 334867.
Prior to day 14 (left dashed line) mice received only saline; and after day 31 (right dashed
line) received only cocaine and/or saline or vehicle (20% v/v DMSO + 25% w/v
cyclodextran). A decrease in average mouse weight was evident by the third day after the
start of SB 334867 exposure (36.1 ± 0.6 g) compared to the day prior to the first SB 334867
administration (38.1 ± 0.9 g). See Results, section 2.1 for details.
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Representative ICSS rate-frequency curves from one mouse before (black circles) and after
injection of saline (white circles, dashed) or cocaine (COC10; white circles, solid). In this
example, baseline pre-injection BSR threshold (θ0) was 83.2 Hz, was not significantly
changed (78.4 Hz) after saline injection; and was lowered by cocaine 10 mg/kg i.p. to 51.5
Hz, or 62% of baseline θ0. See Experimental Procedure, section 4.2 for details.
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Effect of the orexin-A receptor antagonist SB 334867 (gray bars) and vehicle (20% v/v
DMSO + 25% w/v cyclodextrin in sterile normal saline; white bars) on BSR threshold (θ0)
and maximum operant response rate. No significant effect of time after injection was
observed. Data are averaged over 60 minutes and expressed as mean effects ± S.E.M. at
each dose (n = 13).
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Effect of cocaine on BSR threshold (θ0) and maximum operant response rate with (black
circles) or without (white circles) prior administration of the orexin-A receptor antagonist
SB 334867 (30 mg/kg). The first data point at each 15-minute epoch (V) represents the
effects of vehicle (“Cocaine”) or SB 334867 alone (“SB + Cocaine”). Data at each dose and
time point are expressed as mean effects ± S.E.M. (n = 12). * = P < 0.05 vs. vehicle; † = P
< 0.05 vs. cocaine alone.
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Effect of the orexin-A receptor antagonist SB 334867 on preinjection baseline BSR
threshold expressed as charge delivery (in Coulombs, C) at θ0 across the course of the
experiment. No significant change in baseline θ0 was seen during or after every other day
testing with SB ± cocaine (days 14–31). Data are expressed as mean baseline θ0 ± S.E.M. on
each day (n = 12).
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ICSS electrode placements in the medial forebrain bundle at the level of the lateral
hypothalamus (n = 13). Electrode tip locations are plotted on templates from the standard
mouse stereotaxic atlas (Paxinos and Franklin 1996) by manual inspection of Nissl-stained
sections. All electrodes were implanted on the right (m/l = −0.8 mm). See Experimental
Procedure, section 4.3 for details.
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